No connection

Search Results

IINN vs JNJ

IINN
Inspira Technologies Oxy B.H.N. Ltd.
BEARISH
Price
$0.42
Market Cap
$18.5M
Sector
Healthcare
AI Confidence
95%
JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
IINN
--
JNJ
21.55
Forward P/E
IINN
-0.61
JNJ
18.9
P/B Ratio
IINN
6.54
JNJ
7.03
P/S Ratio
IINN
64.07
JNJ
6.09
EV/EBITDA
IINN
-1.18
JNJ
17.81

Profitability

Gross Margin
IINN
0.69%
JNJ
68.08%
Operating Margin
IINN
-4713.84%
JNJ
23.97%
Profit Margin
IINN
0.0%
JNJ
28.46%
ROE
IINN
-397.89%
JNJ
35.03%
ROA
IINN
-126.98%
JNJ
8.68%

Growth

Revenue Growth
IINN
--
JNJ
9.1%
Earnings Growth
IINN
--
JNJ
48.6%

Financial Health

Debt/Equity
IINN
0.21
JNJ
0.6
Current Ratio
IINN
1.56
JNJ
1.03
Quick Ratio
IINN
1.12
JNJ
0.69

Dividends

Dividend Yield
IINN
--
JNJ
2.19%
Payout Ratio
IINN
0.0%
JNJ
46.6%

AI Verdict

IINN BEARISH

IINN exhibits severe fundamental distress, characterized by a Piotroski F-Score of 4/9, which barely maintains a 'stable' rating despite catastrophic operational metrics. The company's operating margin of -4713.84% and a Price-to-Sales ratio of 64.07 indicate a massive disconnect between market valuation and actual revenue generation. With a 5-year price decline of 91% and a technical trend score of 0/100, the stock is in a persistent freefall. The absence of an Altman Z-Score and Graham Number further underscores the lack of positive earnings or stable equity to support a traditional valuation.

Strengths
Low Debt/Equity ratio (0.21)
Current Ratio of 1.56 suggests adequate short-term liquidity
Quick Ratio of 1.12 indicates ability to cover immediate liabilities
Risks
Extreme operational inefficiency (Operating Margin: -4713.84%)
Negligible Gross Margin (0.69%) suggesting no pricing power or high COGS
Severe valuation bubble relative to sales (P/S: 64.07)
JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69

Compare Another Pair

IINN vs JNJ: Head-to-Head Comparison

This page compares Inspira Technologies Oxy B.H.N. Ltd. (IINN) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile